Simple Summary The management of non-small cell lung cancer with a common EGFR
mutation has evolved over the past decades. While frontline use of second-or third …

PURPOSE To investigate the efficacy of gefitinib as an adjuvant therapy for non–small-cell
lung cancer patients with EGFR mutation. PATIENTS AND METHODS IMPACT …

Simple Summary Targeted therapies have emerged as newer systemic options for certain
cancers. EGFR-directed Tyrosine Kinase Inhibitors (EGFR-TKIs), which have several …

Patients with non-small-cell lung cancer (NSCLC), harboring Epidermal Growth Factor
Receptor (EGFR) mutations, are more susceptible to brain metastases (BM). Comparisons of …

Simple Summary Radiotherapy, in the form of either whole-brain radiotherapy (WBRT) or
stereotactic radiosurgery (SRS), continues as the standard of care for patients of non-small …

Patients with non-small cell lung cancer (NSCLC) and de novo brain metastasis (BM) have
poor prognosis. We aim to investigate the characteristic of brain magnetic resonance (MR) …

The neurobiology drug discovery landscape has transformed over the past decade or so by
the discovery of allosteric modulators of receptor superfamilies. A wide range of …

Introduction: Traditionally, brain metastases have been treated with stereotactic radiosurgery
(SRS), whole-brain radiation (WBRT), and/or surgical resection. Non-small cell lung cancers …

Nonsmall cell lung cancer is the most common carcinoma in Asia with more than half
identified as epidermal growth factor receptor mutation-positive (EGFRm+). First-and second …

Background The aim of this study was to survey prognostic factors, particularly those
focusing on epidermal growth factor receptor (EGFR) mutations, of patients with non-small …